One of the most exciting areas of glaucoma research has little to do with eye pressure.
For decades, ophthalmologists have known that lowering intraocular pressure (IOP) slows the progression of glaucoma. In fact, reducing eye pressure remains the only treatment that has consistently been proven to preserve vision in patients with glaucoma.
But an important question remains:
What if we could protect the optic nerve directly, even beyond lowering eye pressure?
This concept is known as neuroprotection, and among currently available glaucoma medications, brimonidine has received more attention than perhaps any other eye drop for its potential neuroprotective properties.
So, does brimonidine actually protect the optic nerve?
The answer is interesting—and a bit more complicated than a simple yes or no answer.
What Is Neuroprotection?
Glaucoma is often thought of as a disease that at least in part is caused by elevated eye pressure.
While pressure is the most important treatable risk factor, glaucoma is actually a neurodegenerative disease. The cells that make up the optic nerve, called retinal ganglion cells, gradually become injured and eventually die. This results ultimately in vision loss if left unchecked.
Lowering eye pressure reduces stress on these cells, but researchers have long wondered whether medications could also help the nerve cells survive by acting directly on their biology.
That strategy is called neuroprotection.
A neuroprotective treatment would ideally preserve retinal ganglion cells even after accounting for its pressure-lowering effect.
Why Did Researchers Become Interested in Brimonidine?
Brimonidine is a medication that has been used for glaucoma treatment since the 1990s.
Its primary job is to lower eye pressure by reducing the amount of fluid produced inside the eye while also modestly improving fluid outflow.
However, laboratory experiments began showing something unexpected.
Researchers observed that retinal ganglion cells exposed to brimonidine appeared to survive injury better than untreated cells. Over time, numerous animal studies suggested that brimonidine might protect nerve cells through several mechanisms independent of lowering eye pressure.
These observations sparked tremendous interest because brimonidine was already an FDA-approved medication with an established safety profile.
How Might Brimonidine Protect Nerve Cells?
Although scientists are still studying the exact mechanisms, several potential explanations have emerged.
Laboratory studies suggest brimonidine may:
- Increase production of brain-derived neurotrophic factor (BDNF), a protein that helps nerve cells survive.
- Reduce damage caused by glutamate excitotoxicity, a process in which excessive stimulation injures neurons.
- Decrease inflammatory signaling within the retina.
- Improve retinal ganglion cell survival following ischemic or mechanical injury.
- Reduce programmed cell death (apoptosis) in retinal ganglion cells.
These findings have been reproduced in multiple animal models of glaucoma and optic nerve injury, making the biological rationale for neuroprotection quite compelling.
What Have Animal Studies Shown?
Preclinical research has been remarkably consistent.
In rodents and other laboratory models, topical brimonidine has been shown to:
- Improve survival of retinal ganglion cells
- Preserve retinal function after ischemic injury
- Maintain levels of neurotrophic factors such as BDNF
- Reduce inflammatory changes within retinal tissue
Many investigators consider the experimental evidence supporting brimonidine's neuroprotective effects to be strong.
The challenge has never been demonstrating neuroprotection in animals.
The challenge has been proving that the same effect occurs in human patients with glaucoma.
The LoGTS Trial: The Study That Changed the Conversation
The most frequently cited human study is the Low-Pressure Glaucoma Treatment Study (LoGTS).
LoGTS enrolled patients with normal-tension glaucoma, a form of glaucoma in which optic nerve damage occurs despite relatively normal eye pressure.
Participants were randomly assigned to receive either:
- Brimonidine 0.2%
- Timolol 0.5%
Importantly, both medications lowered eye pressure by a similar amount.
If pressure lowering was essentially equivalent, any difference in visual outcomes might suggest an additional protective effect.
The investigators found that patients receiving brimonidine experienced significantly less visual field progression than those receiving timolol.
These findings generated enormous excitement because they suggested brimonidine might be protecting the optic nerve through mechanisms beyond lowering eye pressure.
Why Isn't Brimonidine Considered a Proven Neuroprotective Medication?
Despite the excitement surrounding LoGTS, several important limitations prevent ophthalmologists from concluding that brimonidine definitively provides neuroprotection.
High Dropout Rate
Nearly half of the patients assigned to brimonidine discontinued treatment during the study, most commonly because of allergic eye reactions.
This raised concerns that the remaining study population might not accurately represent all patients who started treatment.
Only One Major Clinical Trial
Science is strongest when multiple high-quality studies reach the same conclusion.
To date, LoGTS has not been replicated by another large randomized clinical trial demonstrating the same benefit.
Alternative Explanations
Some researchers have questioned whether the apparent benefit was due entirely to brimonidine—or whether timolol may have had effects on optic nerve blood flow or other physiologic factors that influenced the results.
These questions remain unresolved.
What Do Recent Reviews Conclude?
Over the past decade, several systematic reviews and expert reviews have examined the totality of the evidence.
Their conclusions are remarkably consistent.
Most agree that:
- Laboratory evidence for neuroprotection is strong.
- Animal studies are highly encouraging.
- Human evidence remains limited.
- Current clinical evidence is suggestive but not conclusive.
Larger randomized clinical trials are still needed before brimonidine can be recommended specifically as a neuroprotective therapy.
A 2020 evidence review concluded that the evidence supporting neuroprotection with brimonidine remains inconclusive and requires stronger clinical support before definitive conclusions can be made.
Similarly, recent comprehensive reviews published in 2022 and 2024 describe brimonidine as one of the most promising neuroprotective candidates in glaucoma, while emphasizing that definitive human proof is still lacking.
What Does This Mean for Patients?
Today, ophthalmologists prescribe brimonidine because it is an effective medication for lowering eye pressure.
The possibility that it may also help protect the optic nerve is certainly encouraging, but it should currently be viewed as an active area of research rather than an established clinical benefit.
If future studies confirm its neuroprotective effects, brimonidine could play an even larger role in glaucoma management.
Until then, the cornerstone of glaucoma treatment remains achieving an individualized target eye pressure through medications, laser treatment, surgery—or a combination of these approaches.
The Bottom Line
Brimonidine occupies a unique place in glaucoma research.
Among currently available glaucoma medications, it has some of the strongest laboratory evidence supporting potential neuroprotective effects. Animal studies have repeatedly demonstrated improved survival of retinal ganglion cells, and the landmark LoGTS trial raised the possibility that these benefits might also extend to humans.
However, medicine requires more than promising early results.
At present, the scientific community agrees that there is insufficient clinical evidence to state that brimonidine has proven neuroprotective effects independent of lowering eye pressure.
If you're taking brimonidine—or your ophthalmologist is considering prescribing it—it's important to understand that its primary, evidence-based role remains lowering eye pressure. Whether it also provides additional protection to the optic nerve is a question that researchers continue to investigate.
As always, decisions about glaucoma treatment should be made in partnership with your ophthalmologist, who can recommend the approach that best fits your specific condition and risk factors.
Works Cited
- Krupin T, Liebmann JM, Greenfield DS, et al. A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-Pressure Glaucoma Treatment Study (LoGTS). American Journal of Ophthalmology. 2011.
- Scuteri D, Rombolà L, Watanabe C, et al. Evidence on the Neuroprotective Properties of Brimonidine in Glaucoma. Acta Biomedica. 2020. PMID: 32988470.
- Wang LH, et al. Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Therapies. Pharmaceuticals. 2024.
- Kuo CY, et al. Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance. Journal of Personalized Medicine. 2022.
- Sena DF, Lindsley K. Neuroprotection for Treatment of Glaucoma in Adults. Cochrane Database of Systematic Reviews. 2017.
- Conti F, Romano GL, Eandi CM, et al. Brimonidine Is Neuroprotective in an Animal Paradigm of Retinal Ischemia/Reperfusion Injury. Frontiers in Pharmacology. 2021.
- Doozandeh A, Yazdani S. Neuroprotection in Glaucoma. Journal of Ophthalmic & Vision Research. 2016.